<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Almanac of Clinical Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Almanac of Clinical Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Альманах клинической медицины</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2072-0505</issn><issn publication-format="electronic">2587-9294</issn><publisher><publisher-name xml:lang="en">Moscow Regional Research and Clinical Institute (MONIKI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">17561</article-id><article-id pub-id-type="doi">10.18786/2072-0505-2025-53-027</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Prognostic value of microRNA-143-3p and -451a levels at five year follow up in patients with coronary atherosclerosis</article-title><trans-title-group xml:lang="ru"><trans-title>Прогностическое значение микроРНК 143-3p и 451a при пятилетнем наблюдении у пациентов с атеросклерозом коронарных артерий</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8209-2791</contrib-id><name-alternatives><name xml:lang="en"><surname>Shchekochikhin</surname><given-names>Dmitry Yu.</given-names></name><name xml:lang="ru"><surname>Щекочихин</surname><given-names>Дмитрий Юрьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Associate Professor, Chair of Cardiology, Functional and Ultrasound Diagnostics, N.V. Sklifosovsky Institute of Clinical Medicine</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент кафедры кардиологии, функциональной и ультразвуковой диагностики Института клинической медицины имени Н.В. Склифосовского</p></bio><email>agishm@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7841-9579</contrib-id><name-alternatives><name xml:lang="en"><surname>Birg</surname><given-names>Anna B.</given-names></name><name xml:lang="ru"><surname>Бирг</surname><given-names>Анна Борисовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Research Trainee, Chair of Cardiology, Functional and Ultrasound Diagnostics, N.V. Sklifosovsky Institute of Clinical Medicine</p></bio><bio xml:lang="ru"><p>стажер-исследователь кафедры кардиологии, функциональной и ультразвуковой диагностики Института клинической медицины имени Н.В. Склифосовского</p></bio><email>birg_a_b@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4253-1646</contrib-id><name-alternatives><name xml:lang="en"><surname>Erdniev</surname><given-names>Tamerlan N.</given-names></name><name xml:lang="ru"><surname>Эрдниев</surname><given-names>Тамерлан Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Resident, Chair of Cardiology, Functional and Ultrasound Diagnostics, N.V. Sklifosovsky Institute of Clinical Medicine</p></bio><bio xml:lang="ru"><p>ординатор кафедры кардиологии, функциональной и ультразвуковой диагностики Института клинической медицины имени Н.В. Склифосовского</p></bio><email>tamir202256@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0657-4446</contrib-id><name-alternatives><name xml:lang="en"><surname>Nartova</surname><given-names>Anna A.</given-names></name><name xml:lang="ru"><surname>Нартова</surname><given-names>Анна Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Postgraduate Student, Institute of Personalized Cardiology</p></bio><bio xml:lang="ru"><p>аспирант Института персонализированной кардиологии</p></bio><email>nartovaanna@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2735-076X</contrib-id><name-alternatives><name xml:lang="en"><surname>Rozhkov</surname><given-names>Andrey N.</given-names></name><name xml:lang="ru"><surname>Рожков</surname><given-names>Андрей Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Research Fellow, Institute of Personalized Cardiology</p></bio><bio xml:lang="ru"><p>науч. сотр. Института персонализированной кардиологии</p></bio><email>arozhkov@outlook.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5124-6383</contrib-id><name-alternatives><name xml:lang="en"><surname>Kopylov</surname><given-names>Philipp Yu.</given-names></name><name xml:lang="ru"><surname>Копылов</surname><given-names>Филипп Юрьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Chair of Cardiology, Functional and Ultrasound Diagnostics, Head of the Institute of Personalized Cardiology</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор кафедры кардиологии, функциональной и ультразвуковой диагностики Института клинической медицины имени Н.В. Склифосовского, директор Института персонализированной кардиологии</p></bio><email>fjk@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-04-23" publication-format="electronic"><day>23</day><month>04</month><year>2026</year></pub-date><volume>53</volume><issue>6</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>296</fpage><lpage>305</lpage><history><date date-type="received" iso-8601-date="2025-11-25"><day>25</day><month>11</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2026-02-20"><day>20</day><month>02</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Shchekochikhin D.Y., Birg A.B., Erdniev T.N., Nartova A.A., Rozhkov A.N., Kopylov P.Y.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Щекочихин Д.Ю., Бирг А.Б., Эрдниев Т.Н., Нартова А.А., Рожков А.Н., Копылов Ф.Ю.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Shchekochikhin D.Y., Birg A.B., Erdniev T.N., Nartova A.A., Rozhkov A.N., Kopylov P.Y.</copyright-holder><copyright-holder xml:lang="ru">Щекочихин Д.Ю., Бирг А.Б., Эрдниев Т.Н., Нартова А.А., Рожков А.Н., Копылов Ф.Ю.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://almclinmed.ru/jour/article/view/17561">https://almclinmed.ru/jour/article/view/17561</self-uri><abstract xml:lang="en"><p><bold>Background:</bold> Risk stratification for adverse cardiovascular outcomes is a key challenge in clinical cardiology. In addition to traditional risk scores, various other markers, including circulating microRNAs, have been actively investigated in recent years as a potential tool for personalized prognosis.</p> <p><bold>Aim:</bold> To assess the prognostic value of baseline microRNA levels in patients with asymptomatic coronary atherosclerosis detected by multislice computed tomography (MSCT) during long-term follow-up.</p> <p><bold>Methods: </bold>The retrospective analysis included data from 30 patients with asymptomatic coronary atherosclerosis confirmed by MSCT. At baseline, plasma levels of 15 circulating microRNAs were measured in all patients using NucleoSpin miRNA Plasma kits (MACHEREY-NAGEL, Germany): miR-195p, miR-126-3p, miR-205-5p, miR-126-5p, miR-21-5p, miR-143-3p, miR-223-3p, miR-145-5p, miR-29b-3p, miR-146a-5p, miR-92a-3p, miR-150-5p, miR-23a-3p, miR-181b-5p, miR-451a. Information on clinical outcomes within 5 years after enrollment was obtained from the Unified State Health Information System (USHIS, Russia). Endpoints were acute myocardial infarction (AMI), stroke, all-cause mortality, and a composite endpoint (AMI / stroke / mortality).</p> <p><bold>Results:</bold> Among the 30 patients with asymptomatic atherosclerosis on MSCT (mean age 70 ± 9.8 years, 11 men), adverse outcomes were recorded in 7 patients during the 5-year follow-up, while 23 patients remained event-free. In univariate Cox analysis, only two microRNAs showed a statistically significant association with the outcome (AMI, stroke, and all-cause mortality): for miR-143-3p, the hazard ratio (HR) was 0.724 (95% confidence interval [CI] 0.539–0.972; p = 0.032); for miR-451a, HR was 27.872 (95% CI 1.125–690.637; p = 0.042). ROC analysis revealed borderline significance in predicting adverse events for miR-143-3p (sensitivity 71.4%, specificity 73.9%; p = 0.059) and for miR-451a (sensitivity 71.4%, specificity 87.0%; p = 0.066). In multivariable Cox regression adjusted for the Framingham risk score, a higher miR-143-3p level was independently associated with a reduced risk of all-cause death (HR 0.71; 95% CI 0.52–0.96). After adjustment for the Multi-Ethnic Study of Atherosclerosis (MESA) risk score, the high-risk category of miR-143-3p was associated with an increased risk of reaching the composite endpoint (HR 607.997; 95% CI 4.606–8024.582).</p> <p><bold>Conclusion:</bold> Among the 15 microRNAs studied, miR-143-3p and miR-451a demonstrated an association with the development of adverse outcomes in patients with asymptomatic coronary atherosclerosis. These findings point to the potential prognostic value of these microRNAs, but require confirmation in studies with larger patient samples.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Актуальность.</bold> Стратификация риска неблагоприятных сердечно-сосудистых исходов – одна из ключевых задач клинической кардиологии. В дополнение к традиционным шкалам риска в последние годы активно изучаются различные другие маркеры, включая циркулирующие микроРНК, как потенциальный инструмент персонализированной оценки прогноза.</p> <p><bold>Цель</bold> – оценить прогностическую значимость исходных уровней микроРНК у пациентов с бессимптомным атеросклерозом коронарных артерий, выявленным по данным мультиспиральной компьютерной томографии (МСКТ), при долгосрочном наблюдении.</p> <p><bold>Материал и методы.</bold> В ретроспективный анализ включены данные 30 пациентов с бессимптомным атеросклерозом коронарных артерий, подтвержденным результатами МСКТ. Исходно у всех пациентов были определены уровни 15 циркулирующих микроРНК в плазме крови с помощью наборов NucleoSpin miRNA Plasma (MACHEREY-NAGEL, Германия): miR-195p, miR-126-3p, miR-205-5p, miR-126-5p, miR-21-5p, miR-143-3p, miR-223-3p, miR-145-5p, miR-29b-3p, miR-146a-5p, miR-92a-3p, miR-150-5p, miR-23a-3p, miR-181b-5p, miR-451a. Информация о клинических исходах в течение 5 лет после включения в исследование получена из Единой государственной информационной системы в сфере здравоохранения. Конечными точками были острый инфаркт миокарда (ОИМ), острое нарушение мозгового кровообращения (ОНМК), смерть от всех причин и комбинированная конечная точка (ОИМ / ОНМК / смерть).</p> <p><bold>Результаты.</bold> Из 30 пациентов с бессимптомным атеросклерозом по данным МСКТ (средний возраст – 70 ± 9,8 года, 11 мужчин) в течение 5 лет неблагоприятные исходы зарегистрированы у 7 человек, 23 человека не имели этих исходов. В однофакторном анализе Кокса уровень только двух микроРНК имел статистически значимую связь с исходом (ОИМ, ОНМК и смерти от всех причин): для miR-143-3p относительный риск (ОР) составил 0,724, 95% доверительный интервал (ДИ) 0,539–0,972 (p = 0,032), для miR-451a – ОР 27,872, 95% ДИ 1,125–690,637 (p = 0,042). ROC-анализ показал пограничную значимость уровня miR-143-3p при прогнозировании неблагоприятных событий (чувствительность – 71,4%, специфичность – 73,9%; p = 0,059), а также miR-451a (чувствительность – 71,4%, специфичность – 87%; p = 0,066). В многофакторном регрессионном анализе Кокса, скорректированном с учетом шкалы риска Framingham, более высокий уровень miR-143-3p был независимо связан со сниженным риском смерти от всех причин (ОР 0,71, 95% ДИ 0,52–0,96). При корректировке на шкалу MESA категория высокого риска miR-143-3p ассоциировалась с повышенным риском достижения комбинированной конечной точки (ОР 607,997, 95% ДИ 4,606–8024,582).</p> <p><bold>Заключение.</bold> Среди 15 изученных микроРНК miR-143-3p и miR-451a продемонстрировали ассоциацию с развитием неблагоприятных исходов у пациентов с бессимптомным атеросклерозом коронарных артерий. Полученные результаты указывают на потенциальную прогностическую значимость данных микроРНК, однако требуют подтверждения в исследованиях с большей выборкой пациентов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>microRNA</kwd><kwd>miR-143-3p</kwd><kwd>miR-451a</kwd><kwd>atherosclerosis</kwd><kwd>cardiovascular risk</kwd><kwd>prognosis</kwd><kwd>acute myocardial infarction</kwd><kwd>stroke</kwd><kwd>mortality</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>микроРНК</kwd><kwd>miR-143-3p</kwd><kwd>miR-451a</kwd><kwd>атеросклероз</kwd><kwd>сердечно-сосудистый риск</kwd><kwd>прогноз</kwd><kwd>острый инфаркт миокарда</kwd><kwd>острое нарушение мозгового кровообращения</kwd><kwd>смертность</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Tejada-Vera B, Bastian BA, Curtin SC. Deaths: Leading causes for 2023. Natl Vital Stat Rep. 2025;(10):1. doi: 10.15620/cdc/174607.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Zaidi SA, Fan Z, Chauhdari T, Ding Y. MicroRNA regulatory dynamic, emerging diagnostic and therapeutic frontier in atherosclerosis. Microvasc Res. 2025;160:104818. doi: 10.1016/j.mvr.2025.104818.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Turko R, Hajja A, Magableh AM, Omer MH, Shafqat A, Khan MI, Yaqinuddin A. The emerging role of miRNAs in biological aging and age-related diseases. Noncoding RNA Res. 2025;13:131–152. doi: 10.1016/j.ncrna.2025.05.002.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Colpaert RMW, Calore M. MicroRNAs in cardiac diseases. Cells. 2019;8(7):737. doi: 10.3390/cells8070737.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Yildiz M, Ozkan U, Budak M. The heart's small molecules: The importance of microRNAs in cardiovascular health. J Clin Med. 2025;14(21):7454. doi: 10.3390/jcm14217454.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Rozhkov AN, Shchekochikhin DY, Ashikhmin YI, Mitina YO, Evgrafova VV, Zhelankin AV, Gognieva DG, Akselrod AS, Kopylov PY. The profile of circulating blood microRNAs in outpatients with vulnerable and stable atherosclerotic plaques: Associations with cardiovascular risks. Noncoding RNA. 2022;8(4):47. doi: 10.3390/ncrna8040047.</mixed-citation></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Polyakova EA, Zaraiskii MI, Berkovich OA, Baranova EI, Shlyakhto EV. [The role of small noncoding RNAs in the pathogenesis of coronary arteries atherosclerosis]. Translational Medicine. 2018;5(3):5–14. Russian. doi: 10.18705/2311-4495-2018-5-3-5-14.</mixed-citation><mixed-citation xml:lang="ru">Полякова ЕА, Зарайский МИ, Беркович ОА, Баранова ЕИ, Шляхто ЕВ. Роль малых некодирующих РНК в патогенезе атеросклероза коронарных артерий. Трансляционная медицина. 2018;5(3):5–14. doi: 10.18705/2311-4495-2018-5-3-5-14.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Stonogina DA, Zhelankin AV, Akselrod AS, Generozov EV, Shchekochikhin DIu, Vasilyev SV, Syrkin AL. [Circulating miRNAs as risk biomarkers of cardiovascular complications in patients with coronary artery disease: achievements and difficulties of recent years]. Russian Journal of Cardiology and Cardiovascular Surgery. 2019;12(1):17–24. Russian. doi: 10.17116/kardio20191201117.</mixed-citation><mixed-citation xml:lang="ru">Стоногина ДА, Желанкин АВ, Аксельрод АС, Генерозов ЭВ, Щекочихин ДЮ, Васильев СВ, Сыркин АЛ. Циркулирующие микроРНК как биомаркеры риска сердечно-сосудистых осложнений у больных с ИБС: достижения и трудности последних лет. Кардиология и сердечно-сосудистая хирургия. 2019;12(1):17–24. doi: 10.17116/kardio20191201117.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Rozhkov AN, Shchekochikhin DY, Baulina NМ, Matveeva NA, Favorova OO, Akselrod AS, Tebenkova ES, Gognieva DG, Kopylov PY. [Analysis of circulating miRNA levels in coronary heart disease patients with varying degrees of cardiovascular complications risk. Correlations with the MSCT-CA data]. Annals of the Russian Academy of Medical Sciences. 2020;75(4):283–291. Russian. doi: 10.15690/vramn1325.</mixed-citation><mixed-citation xml:lang="ru">Рожков АН, Щекочихин ДЮ, Баулина НМ, Матвеева НА, Фаворова ОО, Аксельрод АС, Тебенькова ЕС, Гогниева ДГ, Копылов ФЮ. Анализ уровней циркулирующих микро-РНК у пациентов с коронарной болезнью сердца при различной степени риска развития сердечно-сосудистых осложнений. Корреляция с данными МСКТ-КА. Вестник Российской академии медицинских наук. 2020;75(4):283–291. doi: 10.15690/vramn1325.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><mixed-citation>Gacoń J, Kabłak-Ziembicka A, Stępień E, Enguita FJ, Karch I, Derlaga B, Żmudka K, Przewłocki T. Decision-making microRNAs (miR-124, -133a/b, -34a and -134) in patients with occluded target vessel in acute coronary syndrome. Kardiol Pol. 2016;74(3):280–288. doi: 10.5603/KP.a2015.0174.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Devaux Y, Mueller M, Haaf P, Goretti E, Twerenbold R, Zangrando J, Vausort M, Reichlin T, Wildi K, Moehring B, Wagner DR, Mueller C. Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain. J Intern Med. 2015;277(2):260–271. doi: 10.1111/joim.12183.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, Qin YW, Jing Q. Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31(6):659–666. doi: 10.1093/eurheartj/ehq013.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K, Kempf T, Wollert KC, Thum T. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol. 2011;51(5):872–875. doi: 10.1016/j.yjmcc.2011.07.011.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Goretti E, Vausort M, Wagner DR, Devaux Y. Association between circulating microRNAs, cardiovascular risk factors and outcome in patients with acute myocardial infarction. Int J Cardiol. 2013;168(4):4548–4550. doi: 10.1016/ j.ijcard.2013.06.092.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Oerlemans MI, Mosterd A, Dekker MS, de Vrey EA, van Mil A, Pasterkamp G, Doevendans PA, Hoes AW, Sluijter JP. Early assessment of acute coronary syndromes in the emergency department: The potential diagnostic value of circulating microRNAs. EMBO Mol Med. 2012;4(11):1176–1185. doi: 10.1002/emmm.201201749.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Bergami M, Fabin N, Cenko E, Bugiardini R, Manfrini O. MicroRNAs as potential biomarkers in coronary artery disease. Curr Top Med Chem. 2023;23(6):454–469. doi: 10.2174/1568026623666221221124530.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Burnjaković B, Atanasković M, Baralić M, Altić A, Nikolov E, Ilić A, Sič A, Stanković Popović V, Bontić A, Gajić S, Stankovic S. Diagnostic, prognostic and therapeutic utility of microRNA-21 in ischemic heart disease. Int J Mol Sci. 2026;27(2):954. doi: 10.3390/ijms27020954.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>González-López P, Yu Y, Lin S, Escribano Ó, Gómez-Hernández A, Gisterå A. Dysregulation of micro-RNA 143-3p as a biomarker of carotid atherosclerosis and the associated immune reactions during disease progression. J Cardiovasc Transl Res. 2024;17(4):768–778. doi: 10.1007/s12265-024-10482-1.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Liu Y, Wu Y, Wang C, Hu W, Zou S, Ren H, Zuo Y, Qu L. MiR-127-3p enhances macrophagic proliferation via disturbing fatty acid profiles and oxidative phosphorylation in atherosclerosis. J Mol Cell Cardiol. 2024;193:36–52. doi: 10.1016/ j.yjmcc.2024.05.010.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D, Suciu N, Cretoiu SM, Voinea SC. miRNAs as biomarkers in disease: Latest findings regarding their role in diagnosis and prognosis. Cells. 2020;9(2):276. doi: 10.3390/cells9020276.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Eitel I, Adams V, Dieterich P, Fuernau G, de Waha S, Desch S, Schuler G, Thiele H. Relation of circulating microRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction. Am Heart J. 2012;164(5):706–714. doi: 10.1016/ j.ahj.2012.08.004.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Yu C, Zhu QP, Xie W, Xu WS, Liu JL, Wang W, Zhang YF, Zhang T, Shao G. MiR-193b-3p regulates gasdermin-D/NLRP3 by targeting the signaling axis inhibition of pyroptosis attenuates myocardial ischemia-reperfusion injury. J Physiol Investig. 2025;68(6):349–357. doi: 10.4103/ejpi.EJPI-D-25-00032.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Ministrini S, Carbone F, Montecucco F. Updating concepts on atherosclerotic inflammation: From pathophysiology to treatment. Eur J Clin Invest. 2021;51(5):e13467. doi: 10.1111/eci.13467.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Jolana L, Kamil D. The role of microRNA in ischemic and hemorrhagic stroke. Curr Drug Deliv. 2017;14(6):816–831. doi: 10.2174/1567201813666160919142212.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Wu X, Zhang X, Li D, Zhu Z. Plasma level of miR-99b may serve as potential diagnostic and short-term prognostic markers in patients with acute cerebral infarction. J Clin Lab Anal. 2020;34(3):e23093. doi: 10.1002/jcla.23093.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Zhou X, Qi L. miR-124 is downregulated in serum of acute cerebral infarct patients and shows diagnostic and prognostic value. Clin Appl Thromb Hemost. 2021;27:10760296211035446. doi: 10.1177/10760296211035446.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Du W, Fan L, Du J. Neuroinflammation-associated miR-106a-5p serves as a biomarker for the diagnosis and prognosis of acute cerebral infarction. BMC Neurol. 2023;23(1):248. doi: 10.1186/s12883-023-03241-3.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Chang C, Wang Y, Wang R, Bao X. Considering context-specific microRNAs in ischemic stroke with three "W": Where, when, and what. Mol Neurobiol. 2024;61(10):7335–7353. doi: 10.1007/s12035-024-04051-5.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Nugrahani ASD, Widiarti W, Ramadhan RN, Dyah Kencono Wungu C, Susilo H, Mohd Amin I. Diagnostic and prognostic value of circulating microRNA-21 in heart failure: A systematic review and meta-analysis. Biomol Biomed. 2025;26(6):912–923. doi: 10.17305/bb.2025.13164.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Alifragki A, Katsi V, Fragkiadakis K, Karagkounis T, Kopidakis N, Kallergis E, Zacharis E, Kampanieris E, Simantirakis E, Tsioufis K, Marketou M. Orchestrating HFpEF: How noncoding RNAs drive pathophysiology and phenotypic outcomes. Int J Mol Sci. 2025;26(24):11937. doi: 10.3390/ijms262411937.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Gilyazova I, Timasheva Y, Chumakova A, Abdeeva G, Plotnikova M, Zagidullin N. The role of microRNAs in the pathophysiology and management of heart failure: From molecular mechanisms to clinical application. Int J Mol Sci. 2025;26(24):12085. doi: 10.3390/ijms262412085.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Keller T, Boeckel JN, Groß S, Klotsche J, Palapies L, Leistner D, Pieper L, Stalla GK, Lehnert H, Silber S, Pittrow D, Maerz W, Dörr M, Wittchen HU, Baumeister SE, Völker U, Felix SB, Dimmeler S, Zeiher AM. Improved risk stratification in prevention by use of a panel of selected circulating microRNAs. Sci Rep. 2017;7(1):4511. doi: 10.1038/s41598-017-04040-w.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Bye A, Røsjø H, Nauman J, Silva GJ, Follestad T, Omland T, Wisløff U. Circulating microRNAs predict future fatal myocardial infarction in healthy individuals – The HUNT study. J Mol Cell Cardiol. 2016;97:162–168. doi: 10.1016/ j.yjmcc.2016.05.009.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Velle-Forbord T, Eidlaug M, Debik J, Sæther JC, Follestad T, Nauman J, Gigante B, Røsjø H, Omland T, Langaas M, Bye A. Circulating microRNAs as predictive biomarkers of myocardial infarction: Evidence from the HUNT study. Atherosclerosis. 2019;289:1–7. doi: 10.1016/j.atherosclerosis.2019.07.024.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Sahu P, Bestepe F, Vehbi S, Ghanem GF, Blanton RM, Icli B. Obesity and heart failure: Mechanistic insights and the regulatory role of micro-RNAs. Genes (Basel). 2025;16(6):647. doi: 10.3390/genes16060647.</mixed-citation></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">Mironova OI, Berdysheva MV, Deeva ES, Elfimova EM. MicroRNA: A clinician’s view of the state of the problem. Part 3: MicroRNA and approaches to the treatment of cardiovascular diseases. Eurasian Heart Journal. 2023;(3):82–88. Russian. doi: 10.38109/2225-1685-2023-3-82-88.</mixed-citation><mixed-citation xml:lang="ru">Миронова ОЮ, Бердышева МВ, Деева ЕС, Елфимова ЕМ. МикроРНК: взгляд клинициста на состояние проблемы. Часть 3: МикроРНК и подходы к лечению сердечно-сосудистых заболеваний. Евразийский кардиологический журнал. 2023;(3):82–88. doi: 10.38109/2225-1685-2023-3-82-88.</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><mixed-citation>Sarzani R, Spannella F, Di Pentima C, Giulietti F, Landolfo M, Allevi M. Molecular therapies in cardiovascular diseases: Small interfering RNA in atherosclerosis, heart failure, and hypertension. Int J Mol Sci. 2023;25(1):328. doi: 10.3390/ijms25010328.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Aimo A, Castiglione V, Emdin M, Lorenzoni V, Vergaro G. Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: A network meta-analysis. Eur Heart J Open. 2025;5(6):oeaf147. doi: 10.1093/ehjopen/oeaf147.</mixed-citation></ref></ref-list></back></article>
